Skip to content

Instantly share code, notes, and snippets.

@htlin222

htlin222/hellow.md

Last active July 26, 2023 07:00
Show Gist options
  • Save htlin222/f5138d30bf43dacd005e20e2a894207f to your computer and use it in GitHub Desktop.
Save htlin222/f5138d30bf43dacd005e20e2a894207f to your computer and use it in GitHub Desktop.
Download ZIP
update
Raw
hellow.md
  1. Longo DL, Armitage JO. A Better Treatment for Advanced-Stage Hodgkin’s Lymphoma? New England Journal of Medicine. 2022;387(4):370-372. doi:10.1056/NEJMe2207639
  2. Choi Y, Diefenbach C. Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma. Current Oncology Reports. 2020;22(1):6-6. doi:10.1007/s11912-020-0866-3
  3. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. New England Journal of Medicine. 2018;378(4):331-344. doi:10.1056/NEJMoa1708984
  4. Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica. 2021;106(4):1129-1137. doi:10.3324/haematol.2019.243238
  5. Epperla N, Hamadani M. Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. Hematology. 2021;2021(1):247-253. doi:10.1182/hematology.2021000256
  6. Driessen J, Tonino SH, Moskowitz AJ, Kersten MJ. How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. 2021;2021(1):240-246. doi:10.1182/hematology.2021000311
  7. Ansell SM, Radford J, Connors JM, et al. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma. New England Journal of Medicine. 2022;387(4):310-320. doi:10.1056/NEJMoa2206125

title 2

title 34

Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment